Immunologic Research

, Volume 65, Issue 1, pp 157–163 | Cite as

Autoimmune reaction after anti-tetanus vaccination—description of four cases and review of the literature

  • N. Ruhrman-Shahar
  • J. Torres-Ruiz
  • P. Rotman-Pikielny
  • Y. LevyEmail author
Environment and Autoimmunity


Autoimmune reaction after vaccination is sporadically reported in the medical literature. Vaccinations are generally safe and have an important role in eradicating endemic diseases worldwide. Nevertheless, the question arises as to whether there is a possibility of post-vaccination autoimmune phenomena. The anti-tetanus vaccine is being used since 1924, and it is part of the recommended immunization schedules for children. There are few reports of autoimmune diseases, such as rheumatoid arthritis and anti-phospholipid syndrome after anti-tetanus vaccination. Herein, we describe four cases, of which we believe, show a clear temporal relation between anti-tetanus vaccination and the appearance of dermatomyositis, systemic lupus erythematosus, type 1 diabetes mellitus and anti-phospholipid syndrome. We also suggest some of the pathogenic mechanisms that promote a pathogenic autoimmune response.


Autoimmune reaction Vaccination Anti-tetanus vaccine Dermatomyositis Systemic lupus erythematosus Type 1 diabetes mellitus Anti-phospholipid syndrome ASIA 


  1. 1.
    Shoenfeld Y, Agmon-Levin N, Tomljenovic L. Vaccines and autoimmunity. Vancouver: Wiley-Blackwell; 2015.CrossRefGoogle Scholar
  2. 2.
    Hua C, Morel J, Ardouin E, Ricard E, Foret J, Mathieu S, et al. Reasons for non-vaccination in French rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2015;54(4):748–50.CrossRefGoogle Scholar
  3. 3.
    Salami S, D’Amelio R. Could autoimmunity be induced by vaccination? Int Rev Immunol. 2010;29(3):247–69.CrossRefGoogle Scholar
  4. 4.
    Benoist C, Mathis D. Autoimmunity provoked by infections; how good is the case for T cell epitope mimicry? Nat Immunol. 2001;2(9):797–801.CrossRefPubMedGoogle Scholar
  5. 5.
    Wraith DC. Vaccination an autoimmune diseases: what is the evidence? Lancet. 2003;362(9396):1659–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, by-stander activation or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006;19(1):80–94.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Shoenfeld Y, Agmon-Levin N. ASIA autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 2013;47:1–16.CrossRefPubMedGoogle Scholar
  9. 9.
    Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488–96.CrossRefPubMedGoogle Scholar
  10. 10.
    Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 2001;84(3):227–9.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990–1994). Pediatr Infect Dis J. 1996;15(1):88–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Nieminen U, Peltola H, Syrjälä MT, Mäkipernaa A, Kekomäki R. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. Acta Paediatr. 1993;82:267–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Jonville-Béra AP, Autret E, Galy-Eyraud C, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-mérieux sérums et vaccins. Pediatr Infect Dis J. 1996;15(1):44–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009;46:S2–14.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Marks JS, Halpin TJ. Guillain–Barré syndrome in recipients of A/New Jersey influenza vaccine. JAMA. 1980;243(24):2490–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Langmuir AD. Guillain–Barré syndrome: the swine influenza virus vaccine incident in the United States of America, 1976–77: preliminary communication. J R Soc Med. 1979;72(9):660–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Eisen DP, McBryde ES. Avoiding Guillain–Barré syndrome following swine origin pandemic H1N1 2009 influenza vaccination. J Infect Dis. 2009;200(10):1627–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Mash D, et al. The Guillain–Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med. 1998;339:1797–802.CrossRefPubMedGoogle Scholar
  19. 19.
    Juurlink DN, Stukel TA, Kwong J, Kopp A, McGeer A, Upshur RE, et al. Guillain–Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med. 2006;166(20):2217–21.CrossRefPubMedGoogle Scholar
  20. 20.
    Hassan W, Oldham R. Reiter’s syndrome and reactive arthritis in health care workers after vaccination. BMJ. 1994;309(6947):94.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Aksu K, Keser G, Doganavsargil E. Reactive arthritis following tetanus and rabies vaccinations. Rheumatol Int. 2006;27(2):209–10.CrossRefPubMedGoogle Scholar
  22. 22.
    Agmon-Levin N, Zafrir Y, Paz Z. Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus. 2009;18(13):1192–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from advisory committee on immunization practice. MMWR Morb Mortal Wkly Rep. 2011;60(1):13–5.Google Scholar
  24. 24.
    Meir A, Rotman-Pikielny P, Levy Y. Antiphospholipid syndrome following a diphtheria-tetanus vaccination: coincidence vs. causality. Isr Med Assoc J. 2010;12(10):638–9.Google Scholar
  25. 25.
    Zafrir Y, Agmon-Levin N, Paz Z, Shilton T, Shoenfeld Y. Autoimmunity following Hepatitis B vaccine as part of the spectrum of ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’ (ASIA): analysis of 93 cases. Lupus. 2012;21(2):146–52.CrossRefPubMedGoogle Scholar
  26. 26.
    Cerpa-Cruz S, Paredes-Casillas P, Landeros Navarro E, Bernard-Medina AG, Martinez-Bonilla G, Gutierrez-Urena S. Adverse events following immunization with vaccines containing adjuvants. Immunol Res. 2013;56(2–3):299–303.CrossRefPubMedGoogle Scholar
  27. 27.
    Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009;18:1217–25.CrossRefPubMedGoogle Scholar
  28. 28.
    Guimaraes LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190–209.CrossRefPubMedGoogle Scholar
  29. 29.
    Ghimire TR, Benson RA, Garside P, Brewer JM. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol Lett. 2012;147(1–2):55–62.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol. 2012;61(Pt 7):927–34.CrossRefPubMedGoogle Scholar
  31. 31.
    Cruz-Tapias P, Agmon-Levin N, Israeli E, Anaya JM, Shoenfeld Y. Autoimmune (Auto-inflammatory) syndrome induced by adjuvants (ASIA): animal models as a proof of concept. Curr Med Chem. 2013;20:4030–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease. Clin Rev Allergy Immunol. 2011;41(2):163–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Agmon-Levin N, Arango MT, Kivity S, Katzav A, Gilburd B, Blank M, et al. Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model. J Autoimmun. 2014;54:21–32.CrossRefPubMedGoogle Scholar
  34. 34.
    Franchi L, Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol. 2008;38(8):2085–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA. The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun. 2001;69(2):1151–9.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Ligi D, Santi M, Croce L, Mannello F. Aluminum induces inflammatory and proteolytic alterations in human monocytic cell line. J Inorg Biochem. 2015;152:190–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010;10(3):346–52.CrossRefPubMedGoogle Scholar
  38. 38.
    Venalis P, Lundberg IE. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford). 2014;53(3):397–405.CrossRefGoogle Scholar
  39. 39.
    O’Hanlon TP, Carrick DM, Arnett FC, Reveille JD, Carrington M, Gao X, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies. Medicine. 2005;84(6):338–49.CrossRefPubMedGoogle Scholar
  40. 40.
    Gherardi RK, Authier FJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus. 2012;21:184–9.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain. 2001;124:1821–31.CrossRefPubMedGoogle Scholar
  42. 42.
    Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Oshako-Higami S, et al. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol. 2002;14(8):917–24.CrossRefPubMedGoogle Scholar
  43. 43.
    Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol. 1998;24:73–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Ronnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus. 2008;17(5):394–9.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Grammatikos AP, Tsokos GC. Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus. Trends Mol Med. 2012;18(2):101–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 2008;58(1):251–62.CrossRefPubMedGoogle Scholar
  47. 47.
    Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012;42(1):102–11.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Doria A, Sarzi-Puttini P, Shoenfeld Y. Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. Autoimmun Rev. 2008;8(1):1–4.CrossRefPubMedGoogle Scholar
  49. 49.
    Fourneau JM, Bach JM, van Endert PM, Bach JF. The elusive case for a role of mimicry in autoimmune diseases. Mol Immunol. 2004;40:1095–102.CrossRefPubMedGoogle Scholar
  50. 50.
    Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol. 2010;87:385–95.CrossRefPubMedGoogle Scholar
  51. 51.
    Aslanidis S, Pyrpasopoulou A, Kontotasios K, Doumas S, Zamboulis C. Parvovirus B19 infection and systemic lupus erythematosus: activation of an aberrant pathway? Eur J Intern Med. 2008;19(5):314–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Boele LC, Bajramovic JJ, De Vries AM, Voskamp-Visser IA, Kaman WE, Van Der Kleij D. Activation of toll-like receptors and dendritic cells by a broad range of bacterial molecules. Cell Immunol. 2009;255(1–2):17–25.CrossRefPubMedGoogle Scholar
  53. 53.
    Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50(6):1861–72.CrossRefPubMedGoogle Scholar
  54. 54.
    Gottenberg JE, Chiocchia G. Dendritic cells and interferon-mediated autoimmunity. Biochimie. 2007;89:856–71.CrossRefPubMedGoogle Scholar
  55. 55.
    Richardson SJ, Willcox A, Bone AJ, Morgan NG, Foulis AK. Immunopathology of the human pancreas in type-I diabetes. Semin Immunopathol. 2011;33(1):9–21.CrossRefPubMedGoogle Scholar
  56. 56.
    Hviid A, Stellfeld M, Wohlfarhrt J, Melbye M. Childhood vaccination and type 1 diabetes. N Engl J Med. 2004;350(14):1398–404.CrossRefPubMedGoogle Scholar
  57. 57.
    Coppieters KT, Roep BO, Von Herrath MG. Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology. Semin Immunopathol. 2011;33(1):1–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Reynaud Q, Lega JC, Mismetti P, Chapelle C, Wahl D, Cathénebras P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014;13(6):595–608.CrossRefPubMedGoogle Scholar
  59. 59.
    Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to β2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Investig. 2002;109(6):797–804.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Inic-Kanada A, Stojanovic M, Zivkovic I, Kosec D, Micic M, Petrusic V, et al. Murine monoclonal antibody 26 raised against tetanus toxoid cross-reacts with beta2-glycoprotein I: its characteristics and role in molecular mimicry. Am J Reprod Immunol. 2009;61(1):39–51.CrossRefPubMedGoogle Scholar
  61. 61.
    Zivkovic I, Stojanovic M, Petrusic V, Inic-Kanada A, Dimitrijevic L. Induction of APS after TTd hyper-immunization has a different outcome in BALB/c and C57BL/6 mice. Am J Reprod Immunol. 2011;65(5):492–502.CrossRefPubMedGoogle Scholar
  62. 62.
    Petrusic V, Zivkovic I, Muhandes L, Dimitrijevic R, Stojanovic M, Dimitrijevic L. Infection-induced autoantibodies and pregnancy related pathology: an animal model. Reprod Fertil Dev. 2014;26(4):578–86.CrossRefPubMedGoogle Scholar
  63. 63.
    Petrusic V, Todorovic N, Zivkovic I, Dimitrijević R, Muhandes L, Rajnpreht I, et al. Autoantibody response and pregnancy-related pathology induced by combined LPS and tetanus toxoid hyperimmunization in BALB/c and C57BL/6 mice. Autoimmunity. 2015;48(2):87–99.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • N. Ruhrman-Shahar
    • 1
  • J. Torres-Ruiz
    • 2
  • P. Rotman-Pikielny
    • 1
  • Y. Levy
    • 1
    Email author
  1. 1.Department of Medicine EMeir Medical Center, Kfar-Saba (Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel)Kfar-SabaIsrael
  2. 2.Department of Immunology and RheumatologyInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico CityMexico

Personalised recommendations